



Docket No.: 30847/2048-004
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Anna Helgadottir

Application No.: 10/829,674

Filed: April 22, 2004

For: SUSCEPTIBILITY GENE FOR
MYOCARDIAL INFARCTION AND STROKE

Confirmation No.: 6838

Art Unit: 1634

Examiner: J.A. Goldberg

DECLARATION OF ANDREI MANOLESCU, PH.D., UNDER 37 C.F.R. § 1.132

I, Andrei Manolescu, hereby declare as follows that:

1. I am a scientist and statistician who has worked at deCODE genetics, ehf. ("deCODE") since 1999 as a statistician and research scientist. My *curriculum vitae* is attached hereto.
2. I am familiar with the above-identified U.S. patent application and deCODE's research project involving the association between FLAP haplotypes and increased risk for myocardial infarction. I have been involved as part of the research team at deCODE that studies this association and have personally been involved in the statistical analysis of data from which the correlation between FLAP haplotypes and MI has been observed and confirmed. I am providing this declaration to make available to the Examiner additional data and analysis of this phenomenon. I have personal knowledge of the information in this declaration, and my use of the pronoun "we" refers to the deCODE team involved in this research project, of which I am a part.

The discovery of HapA and the replication studies in deCODE

3. In 2004 deCODE discovered and published the association of a haplotype variant of the FLAP gene (5-lipoxygenase activating protein, also known as ALOX5AP) with Myocardial Infarction (MI) and stroke in an Icelandic cohort of 779 MI patients, 702 Stroke patients, and 624 population controls. We called it HapA and it was defined by four single nucleotide polymorphisms

(SNPs) in linkage-disequilibrium situated within the gene in an interval of 33 kilobases: G SG13S25, T SG13S114, G SG13S89, A SG13S32. We selected this haplotype after a large number of statistical tests identifying it as significantly associated with MI. The odds ratio (OR) was 1.8, and the association remained significant after correcting for multiple comparisons with $P=0.005$ (Helgadóttir et al, 2004).

4. After the discovery of HapA deCODE published a replication of the association with stroke in a Scottish cohort (Helgadóttir et al., 2005).

5. The deCODE research team has collected more data to evaluate the association of FLAP HapA with increased risk of MI. We have genotyped a second Icelandic cohort of 1441 cases and 9811 control individuals who were not used in the discovery phase (here called Iceland 2), and six other foreign cohorts. HapA showed a significant association in Iceland 2, but weaker than in the original cohort Iceland 1, with $OR=1.15$. (See Table 1 below.). This lower OR suggests that the magnitude of the OR initially detected may have been inflated by the selection process. In the groups of patients and controls of Iceland 2 the allelic frequencies were by almost 2% lower and higher respectively, than in Iceland 1. However, the observed association in the Iceland 2 study was statistically significant.

6. We further studied HapA in six non-Icelandic cohorts: four from the United States, one from the United Kingdom (the same cohort as was used in the initial publication Helgadóttir et al 2004) and one from Italy (Verona). The association was in the opposite direction ($OR<1$) in the U.S. group from Philadelphia. All of the other cohorts had OR that were greater than 1 and comparable in magnitude to that in Iceland 2, but only one nominally significant. Results for the Italian cohort have been already published by Girelli et al. (2007): they found no statistically significant association of HapA to MI. We received their samples including a set of additional population controls and genotyped them at deCODE. The results for those are shown in Table 1.

7. We combined the genotype data of the non-Icelandic cohorts using the Mantel-Haenszel model, which estimates a common OR assuming different haplotype frequencies for each group (Mantel and Haenszel, 1959; Woodward, 2005). The result was again significant and very similar to the one obtained in Iceland 2 (Table 1). When the data from all of our replication groups (six non-Icelandic plus Iceland 2, but not original Iceland 1) are pooled, the estimated OR is 1.11 with

$P=0.00054$. These results show that the variant HapA is significantly associated with MI, but the effect is systematically weaker than in our initial publication, and therefore an increased statistical power is needed to replicate it. The OR in the replication groups is free of any selection bias that could have been present in the Iceland 1 cohort.

Replication studies of HapA outside deCODE

8. To my knowledge, publications derived from three additional studies, for which we have no access to genotypes, have reported results on HapA association with MI. Zee *et al.* conducted a study of two groups, 341 MI case-control pairs and 259 stroke case-control pairs, all white males from USA matched in pairs by age and smoking. They found HapA in excess in both type of patients relatively to the controls, but not significantly, $OR=1.18$ $P=0.46$ for MI and $OR=1.11$ $P=0.71$ for stroke. Their analysis was done in a different way than ours, by logistic regression with adjustments for several factors. We thought these adjustments were not necessary, but rather induced some noise. We also thought the case-control pairing was not necessary, but rather reduced the statistical power. Therefore we joined their controls into a single control set and using only their estimated haplotype frequencies we recalculated for the MI patients $OR=1.23$, and $P=0.058$ (using a simple one-sided Chi-squared test with one degree of freedom).

9. In a second publication, Koch *et al.* studied a large set of MI cases and controls from Germany, where again HapA was found in a slight, but not statistically significant, excess in patients.

10. A third paper, by Morgan *et al.*, analyzed data for patients with acute coronary syndrome, i.e. MI or unstable angina, a phenotype slightly different than ours. Morgan *et al.* reported that the HapA frequency was a little lower in the patients than in the controls. In Table 1 we show our results corresponding to the Zee study, but the original results by Koch and Morgan, with one-sided P-values.

Meta-analysis of combined results from deCODE and outside

11. As a statistician with experience studying population genetics, it is my opinion that the results of the other studies are not in contradiction to deCODE's data indicating a statistically significant association between the presence of FLAP HapA and increased risk of MI. In this section of my

declaration I explain my analysis of all of this data.

12. We performed a meta-analysis of all available results, including data from cohorts genotyped at DeCODE and the three external studies. Since we do not have the genotype data behind the external studies, we cannot use the Mantel-Haenszel method in the way we used it for joining the cohorts for which we have genotypes. Instead we can use the more empirical solution of adding the Z-scores of each study s , Z_s (i.e. the standard normal value corresponding to the one-sided P-value) with positive or negative signs if $OR > 1$ or $OR < 1$ respectively, and with weights w_s given by the inverse of the standard errors of the OR estimates:

$$Z = \left(\sum_s w_s Z_s \right) / \sqrt{\sum_s w_s^2},$$

where $w_s = Z_s / \log(OR_s)$. We assume the OR's have log-normal distributions. The combined OR is then given by the formula:

$$\log(OR) = \left(\sum_s w_s^2 \log(OR_s) \right) / \left(\sum_s w_s^2 \right)$$

Again, to avoid the initial selection bias the group Iceland 1 was not included in the meta-analysis.

13. We considered the seven internal replication groups as a single complex cohort represented by the joint P-value and OR already calculated (Table 1). The joint P-value of the four studies, one from deCODE and three external, was 0.00034 and the joint $OR = 1.11$ (Table 1). By adding the external results, with one in the negative direction, the association of HapA to MI became even more significant, the overall P-value was reduced, and the joint OR did not change. Using also the original OR and P-value of Zee et al. for MI, instead of the values recalculated by us, we obtained similar results.

Table 1. Meta-analysis of results using data from deCODE and published results for HapA

Cohort (cases/controls)	P	OR (95% CI)	MI	Controls
Iceland 1 : Nat.Genet.36, 233 (2004)	0.0050	1.80	0.158	0.095
Iceland 2 (1441/9811)	0.013	1.15	0.140	0.124
European Americans				
Philadelphia (725/516)	0.746	0.93	0.159	0.170
Cleveland (653/618)	0.027	1.27	0.162	0.133

Atlanta (762/1302)	0.013	1.24	0.174	0.146
Durham, NC (1314/739)	0.183	1.09	0.146	0.135
United Kingdom (750/726)	0.211	1.09	0.169	0.157
Italy (657/1079)	0.271	1.06	0.181	0.172
All MI Caucasian foreigners (4861/4980)	0.008	1.11 (1.02,1.21)		
All Caucasians replication				
Iceland 2 + US + UK + Italy (6302/14791)	0.00054	1.12 (1.05,1.20)		
Other studies				
Zee et al. (341/600)	0.058	1.23	0.172	0.145
Koch et al. (3657/1211)	0.080	1.10	0.160	0.148
Morgan et al. (811/ 650)	0.840	0.90	0.152	0.165
All replication studies combined	0.00034	1.11 (1.05,1.18)		

Discussion

14. Combining results from several studies is important for estimating the overall effects. It is a way of balancing out the deficiencies in each individual study, like different or insufficient matching of cases and controls. But most importantly combining the results of studies is a way of gaining statistical power by increasing the sample size. Statistical power is essential, especially for a genetic variant whose observed effect is weak, in order to demonstrate a true underlying effect. That is why the meta-analysis is now the state of the art in the genome-wide association (GWA) studies with hundreds of thousands of SNPs.

15. In order to prove the genome-wide significance of a SNP with OR about 1.2 or less, which is usually observed, one needs thousands of cases and controls, which can only be obtained by combining several cohorts together. For example, Easton et al. (2007) combined more than 20 cohorts in order to demonstrate the association of five different SNP's with breast cancer. The overall ORs for these SNPs varied between 1.26 and 1.06, comparable to our result for HapA. The individual ORs for each cohort were spread over a broad interval and some ORs were even smaller than one (Easton et al, Table 2 and Figure 2). In terms of P-values, this means that each cohort had a small contribution, possibly not even nominally significant, but the combined result was statistically significant.

16. Another example is provided by the recent study on prostate cancer, by Gudmundsson et al. (2007). Two variants are shown to be associated with the disease by joining four cohorts from Iceland, Holland, Spain, and USA, with OR=1.2. For both variants, the cohort from Spain did not show significant association (Gudmundsson et al., Table 2 and 3), but the combined P-value was significant. Indeed, a significant P-value in a genome-wide association study has to be much lower than our combined P-value of 0.00034 for HapA, because of the large number of genetic variants tested. Instead we tested only one variant, and our P-value is far below the conventional threshold of 0.05. It would correspond to a P-value of the order of 10^{-9} in a GWA study.

Conclusions

17. We conclude, based on the meta-analysis of all available data, that the FLAP HapA variant is truly associated to an elevated risk for MI. It is my opinion as a statistician that population geneticists and other statisticians would share my opinion that the meta-analysis approach is valid and appropriate and that the association between FLAP HapA and MI is real, based on the available data. The modest OR may indicate that HapA is not functionally causative of MI, but rather a valid surrogate of a yet unknown variant with higher penetrance. This does not change the relevance of the HapA as a diagnostic tool for determining which individuals are at increased risk of developing MI due to the presence of HapA – the effect being about 11% for each copy of HapA present in the genome of an individual.

18. An increase in risk of 11% is by no means insignificant, and can be compared to biomarkers and physiological measures which are generally believed to affect risk of developing cardiovascular disease in a quantitative manner (*e.g.*, blood pressure, cholesterol levels) (Wilson et al. 1998). Also, similar effects to those we observe for HapA have been found for variants recently discovered in published GWA studies and are typical for common polymorphisms in common diseases. My opinion as a statistician (which other statisticians would share) is that one judge's whether an observed increase in risk is a "real" phenomenon based on the overall P-value, and not by the magnitude of the OR. P-value indicates statistical significance, whereas OR indicates the magnitude of the increased risk.

19. The results of the meta-analysis confirm that the association between FLAP HapA and increased risk of MI is indeed significant when combining all available studies. In view of this data,

the HapA status of individuals can be used to determine their individual risk of developing MI – quantitatively determined to be about 11% for each copy of the variant carried by the individual. Moreover, our data identify FLAP as a therapeutically attractive target for MI prophylactic agents.

Statistical methods

20. In each replication test we tested the hypothesis that HapA is in excess in patients, i.e. $OR > 1$, and the P-values displayed in Table 1 are therefore 1-sided. The OR's are calculated assuming the multiplicative model (Falk 1987, Terwilliger 1992). The results for Iceland are corrected for relatedness by simulating genotypes through the Icelandic genealogy (Grant et al., 2006). The deCODE data was analyzed with the software NEMO (Gretarsdottir et al. 2003). NEMO handles uncertainty of phase and missing genotypes through a likelihood procedure using the expectation-maximization algorithm to estimate haplotype frequencies (Lange 2002). Relative to Table 1 included in inventor Helgadóttir's declaration (January 2007) for this patent application, in the present version of Table 1 we updated the lists of patients and controls for each cohort and we included the Italian cohort from Verona.

21. References

ALOX5AP gene and HapA

- A. Helgadóttir, et al., The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke, *Nat.Genet.* 36, 233 (2004).
- A. Helgadóttir, et al., Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. *Am J Hum Genet* 76, 505 (2005).
- D. Girelli et al., ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study, *Eur. J. Hum. Genet.* 15, 959 (2007).
- R. Y. L. Zee et al., Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke. A nested case-control approach, *Stroke* 37, 2007 (2006).
- W. Koch et al., No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population, *Genetics in Medicine* 9, 123 (2007).
- T. M. Morgan et al., Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study, *JAMA* 297, 1552 (2007).

P. W. F. Wilson et al., Prediction of Coronary Heart Disease Using Risk Factor Categories, Circulation. 1998;97:1837-1847

Genomewide association studies

D. F. Easton et al., Genome-wide association study identifies novel breast cancer susceptibility loci, Nature 447, 1087 (2007).

J. Gudmundsson, Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes, Nat. Genet. 39, 977 (2007).

Statistical methods

N. Mantel and W. Haenszel, J. Natl. Cancer Inst. 22, 719 (1959).

M. Woodward, Epidemiology Study Design and Data Analysis, Champan & Hall/CRC, 2-nd edition, chapter 4 (2005).

C. T. Falk and P. Rubinstein, Haplotype relative risks: an easy reliable way construct a proper control sample for risk calculations, Ann Hum Genet 51, 227 (1987).

22. I further declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both (18 U.S.C. § 1001), and may jeopardize the validity of the application or any patent issuing thereon.

Dated: Oct. 16 2007

A. Manolescu

Andrei Manolescu, Ph.D.

Curriculum vitae**Andrei Manolescu****Personal data**

Family name: Manolescu

First name: Andrei (male)

Born: 24 March 1958, Bucharest, Romania

Nationality: Romanian

Citizenship: Romanian and Icelandic

Marital status: married, two children

Professional data

Profession: physicist

Present address

Decode Genetics, Sturlugata 8, IS-101 Reykjavik

E-mail manoles@decode.is

Phone: + 354 1970 1926

Address after 1-st January 2008

School of Science and Engineering,

Reykjavik University Kringlan 1, IS-103 Reykjavik

Education

1978-1983: University of Bucharest, Faculty of Physics.

1989-1992: doctorate at the Institute of Atomic Physics, Bucharest;

Thesis: "Contributions to the study of the response and correlation functions in quantum many-body systems"

Positions

1983-1985: physicist at Machine-Tools Factory, Bucharest, nondestructive defectoscopy.

1985-1999: research position at the National Institute of Materials Physics, Principal Researcher 1 since 1995 (the highest rank).

1995-2002: Associate Member of the International Centre for Theoretical Physics, Trieste, Italy.

1999-2007: Statistician, Research Scientist at Decode Genetics, Reykjavik, Iceland.

Academic title: Doctor in Physics since 1992.

Expertise in genetics

Statistical analysis of genetic data for linkage and association of genes with complex diseases. Cardiovascular diseases: myocardial infarction, stroke, atherosclerosis, hypertension. Cancer: prostate cancer, breast cancer. Linkage disequilibrium and haplotype analysis. Quantitative trait analysis by linear regression methods. Population stratification.

Expertise in physics

Two-dimensional systems in magnetic fields, screening, exchange, and other many-body Coulomb effects, edge states, transport and electromagnetic absorption in modulated systems, electronic states in periodic electric and magnetic fields, spin splitting, magnetization.

Teaching experience at University of Bucharest (1986-1987) and at University of Iceland (1998-2002).

List of publications in genetics

H. Stefansson, A. Einarsson, R.T. Geirsson, K. Jonsdottir, G. Sverrisdottir, V.G. Gudnadottir, S. Gunnarsdottir, A. Manolescu, J. Gulcher, K. Stefansson, Endometriosis is not associated with or linked to the GALT gene, *Fertility and Sterility* 76, 1019 (2001).

H. Stefansson, R.T. Geirsson, V. Steinthorsdottir, H. Jonsson, A. Manolescu, A. Kong, G. Ingadottir, J. Gulcher, K. Stefansson, Genetic factors contribute to the risk of developing endometriosis, *Human Reproduction* 17, 555 (2002).

K. Kristjansson, A. Manolescu, A. Kristinsson, T. Hardarson, H. Knudsen, S. Ingason, G. Thorleifsson, M.L. Frigge, A. Kong, J. Gulcher, K. Stefansson, Linkage of essential hypertension to chromosome 18q, *Hypertension* 39, 1044 (2002).

H. Stefansson, E. Sigurdsson, V. Steinthorsdottir, S. Bjornsdottir, T. Sigmundsson, S. Ghosh, J. Brynjolfsson, S. Gunnarsdottir, O. Ivarsson, T.T. Chou, O. Hjaltason, B. Birgisdottir, H. Jonsson, V.G. Gudnadottir, E. Gudmundsdottir, A. Bjornsson, B. Ingvarsson, A. Ingason, S. Sigfusson, H. Hardardottir, R.P. Harvey, D. Lai, M.D. Zhou, D. Brunner, V. Mutel, A. Gonzalo, G. Lemke, J. Sainz, G. Johannesson, T. Andreasson, D. Gudbjartsson, A. Manolescu, M.L. Frigge, M.E. Gurney, A. Kong, J. Gulcher, H. Petursson, K. Stefansson, Neuregulin 1 and susceptibility to schizophrenia, *American Journal of Human Genetics* 71, 877 (2002).

H. Jonsson, I. Manolescu, S.E. Stefansson, T. Ingvarsson, H.H. Jonsson, A. Manolescu, J. Gulcher, K. Stefansson, The Inheritance of Hand Osteoarthritis in Iceland, *Arthritis & Rheumatism* 48, 391 (2003).

S. Gretarsdottir, G. Thorleifsson, S. T. Reynisdottir, A. Manolescu, S. Jonsdottir, T. Jonsdottir, T. Gudmundsdottir, S. M. Bjarnadottir, O. B. Einarsson, H. M. Gudjonsson, M. Hawkins, G. Gudmundsson, H. Gudmundsdottir, H. Andrasan, A. S. Gudmundsdottir, M. Sigurdardottir, T. T. Chou, J. Nahmias, S. Goss, S. Sveinbjarnsdottir, E. M. Valdimarsson, F. Jakobsson, U. Agnarsson, V. Gudnason, G. Thorgeirsson, J. Fingerle, M. Gurney, D. Gudbjartsson, M. L. Frigge, A. Kong, K. Stefansson and J. R. Gulcher, The gene encoding phosphodiesterase 4D confers risk of ischemic stroke, *Nature Genetics* 35, 131 (2003).

A. Helgadóttir, A. Manolescu, G. Thorleifsson, S. Gretarsdottir, H. Jonsdottir, U. Thorsteinsdottir, N. J. Samani, G. Gudmundsson, S. F. A. Grant, G. Thorgeirsson, S. Sveinbjornsdottir, E. M. Valdimarsson, S. E. Matthiasson, H. Johannsson, O. Gudmundsdottir, M. E. Gurney, J. Sainz, M. Thorhallsdottir, M. Andresdottir, M. L. Frigge, E. J. Topol, A. Kong, V. Gudnason, H. Hakonarson, J. R. Gulcher and K. Stefansson, The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke, *Nature Genetics* 36, 233 (2004).

A. Helgadóttir, S. Gretarsdottir, D. St. Clair, A. Manolescu, J. Cheung, G. Thorleifsson, A. Pasdar, S. F. A. Grant, L. J. Whalley, H. Hakonarson, U. Thorsteinsdottir, A. Kong, J. Gulcher, K. Stefansson, and M. J. MacLeod, Association between the gene encoding 5-lipoxygenase activating protein and stroke replicated in a Scottish Population, *American Journal of Human Genetics* 76, 505 (2005).

H. Hakonarson, S. Thorvaldsson, A. Helgadóttir, D. Gudbjartsson, F. Zink, M. Andresdottir, A. Manolescu, D. O. Arnar, K. Andersen, A. Sigurdsson, G. Thorgeirsson, A. Jonsson, U. Agnarsson, H. Bjornsdottir, G. Gottskalksson, A. Einarsson, H. Gudmundsdottir, A. E. Adalsteinsdottir, K. Gudmundsson, K. Kristjansson, T. Hardarson, A. Kristinsson, E. J. Topol, J. Gulcher, A. Kong, M. Gurney, G. Thorgeirsson, K. Stefansson, Effects of a 5-Lipoxygenase Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial,

- A. Helgadóttir, A. Manolescu, A. Helgason, G. Thorleifsson, U. Thorsteinsdóttir, D.F. Gudbjartsson, S. Gretarsdóttir, K.P. Magnusson, G. Gudmundsson, A. Hicks, T. Jonsson, S.F.A. Grant, J. Sainz, S.J. O'Brien, S. Sveinbjornsdóttir, E.M. Valdimarsson, S.E. Matthiasson, A.I. Levey, J.L. Abramson, M.P. Reilly, V. Vaccarino, M.L. Wolfe, V. Gudnason, A.A. Quyyumi, E.J. Topol, D.J. Rader, G. Thorgeirsson, J.R. Gulcher, H. Hakonarson, A. Kong, K. Stefansson, A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction, *Nature Genetics* 38, 68 (2006).
- S.F.A. Grant, G. Thorleifsson, I. Reynisdóttir, R. Benediktsson, A. Manolescu, J. Sainz, A. Helgason, H. Stefansson, V. Emilsson, A. Helgadóttir, U. Styrkarsdóttir, K.P. Magnusson, G.B. Walters, E. Palsdóttir, T. Jonsdóttir, T. Gudmundsdóttir, A. Gylfason, J. Saemundsdóttir, R.L. Wilensky, M.P. Reilly, D.J. Rader, Y. Bagger, C. Christiansen, V. Gudnason, G. Sigurdsson, U. Thorsteinsdóttir, J.R. Gulcher, A. Kong, K. Stefansson, Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes, *Nature Genetics* 38, 320 (2006).
- L.T. Amundadóttir, P. Sulem, J. Gudmundsson, A. Helgason, A. Baker, B.A. Agnarsson, A. Sigurdsson, K.R. Benediktsson, J.B. Cazier, J. Sainz, M. Jakobsdóttir, J. Kostic, D.N. Magnusdóttir, S. Ghosh, K. Agnarsson, B. Birgisdóttir, L.L. Roux, A. Olafsdóttir, T. Blondal, Margret Andresdóttir, O.S. Gretarsdóttir, J.T. Bergthorsson, D. Gudbjartsson, A. Gylfason, G. Thorleifsson, A. Manolescu, K. Kristjansson, G. Geirsson, H. Isaksson, J. Douglas, J.E. Johansson, K. Balter, F. Wiklund, J.E. Montie, X. Yu, B.K. Suarez, C. Ober, K. A Cooney, H. Gronberg, W.J. Catalona, G. V. Einarsson, R.B. Barkardóttir, J.R. Gulcher, A. Kong, U. Thorsteinsdóttir, L.A. Stefansson, A common variant associated with prostate cancer in European and African populations, *Nature Genetics* 38, 652 (2006).
- J. Gudmundsson, P. Sulem, A. Manolescu, L.T. Amundadóttir, D. Gudbjartsson, A. Helgason, T. Rafnar, J.T. Bergthorsson, B.A. Agnarsson, A. Baker, A. Sigurdsson, K.R. Benediktsson, M. Jakobsdóttir, J. Xu, T. Blondal, J. Kostic, J.S., Shyamali Ghosh, S.N. Stacey, M. Mouy, J. Saemundsdóttir, V.M. Backman, K. Kristjansson, A. Tres, A.W. Partin, M.T. Albers-Akkers, J.G.I. Marcos, P.C. Walsh, D.W. Swinkels, S. Navarrete, S.D. Isaacs, K.K. Aben, T. Graif, J. Cashy, M. Ruiz-Echarri, K.E. Wiley, B.K. Suarez, J.A. Witjes, M. Frigge, C. Ober, E. Jonsson, G.V. Einarsson, J.I. Mayordomo, L.A. Kiemeny, W.B. Isaacs, W.J. Catalona, R.B. Barkardóttir, J.R. Gulcher, U. Thorsteinsdóttir, A. Kong and K. Stefansson, Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24, *Nature Genetics* 39, 631-637 (2007)
- A. Helgadóttir, G. Thorleifsson, A. Manolescu, S. Gretarsdóttir, T. Blondal, A. Jonasdóttir, A. Jonasdóttir, A. Sigurdsson, A. Baker, A. Palsson, G. Masson, D. Gudbjartsson, K.P. Magnusson, K. Andersen, A.I. Levey, V.M. Backman, S. Matthiasdóttir, T. Jonsdóttir, S. Palsson, H. Einarsson, S. Gunnarsdóttir, A. Gylfason, V. Vaccarino, W.C. Hooper, M.P. Reilly, C.B. Granger, H. Austin, D.J. Rader, S.H. Shah, A.A. Quyyumi, J.R. Gulcher, G. Thorgeirsson, U. Thorsteinsdóttir, A. Kong, and K. Stefansson, A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction, *Science*, 316, 1491 (2007).

S.N. Stacey, A. Manolescu, P. Sulem, T. Rafnar, J. Gudmundsson, S.A. Gudjonsson, G. Masson, M. Jakobsdottir, S. Thorlacius, A. Helgason, K.K. Aben, L.J. Strobbe, M.T. Albers-Akkers, D.W. Swinkels, B.E. Henderson, L.N. Kolonel, L.L. Marchand, E. Millastre, R. Andres, J. Godino, M.D. Garcia-Prats, E. Polo, A. Tres, M. Mouy, J. Saemundsdottir, V.M. Backman, L. Gudmundsson, K. Kristjansson, J.T. Bergthorsson, J. Kostic, M.L. Frigge, F. Geller, D. Gudbjartsson, H. Sigurdsson, T. Jonsdottir, J. Hrafnkelsson, J. Johannsson, T. Sveinsson, G. Myrdal, H.N. Grimsson, T. Jonsson, S. von Holst, B. Werelius, S. Margolin, A. Lindblom, J.I. Mayordomo, C.A. Haiman, L.A. Kiemeny, O.T. Johannsson, J.R. Gulcher, U. Thorsteinsdottir, A. Kong, K. Stefansson, Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer, *Nature Genetics* 39, 865 (2007).

J. Gudmundsson, P. Sulem, V. Steinthorsdottir, J.T. Bergthorsson, G. Thorleifsson, A. Manolescu, T. Rafnar, D. Gudbjartsson, B.A. Agnarsson, A. Baker, A. Sigurdsson, K.R. Benediktsdottir, M. Jakobsdottir, T. Blondal, S.N. Stacey, A. Helgason, S. Gunnarsdottir, A. Olafsdottir, K. T. Kristinsson, B. Birgisdottir, S. Ghosh, S. Thorlacius, D. Magnusdottir, G. Stefansson, K. Kristjansson, Y. Bagger, R.L. Wilensky, M.P. Reilly, A.D. Morris, C.H. Kimber, A. Adeyemo, Y. Chen, Jie Zhou, Wing-Yee So, P.C.Y. Tong, M.C.Y. Ng, T. Hansen, G. Andersen, K. Borch-Johnsen, T. Jorgensen, A. Tres, F. Fuertes, M. Ruiz-Echarri, L. Asin, B. Saez, E. van Boven, S. Klaver, D.W. Swinkels, K.K. Aben, T. Graif, J. Cashy, B.K. Suarez, O. van Vierssen Trip, M.L. Frigge, C. Ober, M.H. Hofker, C. Wijmenga, C. Christiansen, D.J. Rader, C.N.A. Palmer, C. Rotimi, J.C.N. Chan, O. Pedersen, G. Sigurdsson, R. Benediktsson, E. Jonsson, G.V. Einarsson, J.I. Mayordomo, W.J. Catalona, L.A. Kiemeny, Rosa B Barkardottir, J.R. Gulcher, U. Thorsteinsdottir, A. Kong, K. Stefansson, Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes, *Nature Genetics* 39, 977 (2007).

K. Kostulas, S. Gretarsdottir, V. Kostulas, A. Manolescu, A. Helgadottir, G. Thorleifsson, L.J. Gudmundsson, U. Thorsteinsdottir, J. R. Gulcher, K. Stefansson and J. Hillert, PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden, *J. Neurol Sci.* 24 Jul 2007.

List of publications in physics

A. Costescu, A. Manolescu, and N. Mezincescu, Radiative recombination on K, L, and M shells, *Rev. Roumaine de Phys.* 30, 65-73 (1985).

I. Brandus, A. Costescu, and A. Manolescu, Direct radiative recombination cross sections for arbitrary nS, nP and nD subshells, *J. Phys. B* 20, 4615-4623 (1987).

A. Manolescu, D. Macovei, R. Manaila, R. Grigorovici, and P. Pausescu, Effect of s-p-d hybridization on the EXAFS phase-shifts in amorphous germanium, *J. Noncryst. Solids* 97&98, 519-522 (1987).

A. Manolescu and G. A. Mezincescu, Some consequences of generalized moment inequalities: mass- and charge-response and correlation functions in multicomponent systems, *Phys.Rev. A* 37, 1760-1772 (1988).

A. Manolescu and G. A. Mezincescu, Some constraints on the charge-correlation function for two-dimensional quantum systems, *Phys. Rev. A* 42, 2042-2046 (1990).

A. Manolescu and G. A. Mezincescu, On the relationship between the static response and correlation functions of the spin magnetic moments, *Physica A* 169, 421-429 (1990).

A. Manolescu, Nonlinear screening of a totally occupied Landau level, *Phys. Rev. B* 45, 11829-11836 (1992).

A. Manolescu, Static dielectric susceptibility of the lowest Landau level, *Phys. Rev. B* 46, 2201-2207 (1992).

A. Manolescu, Electrostatic response of two-dimensional electron systems in a strong perpendicular magnetic field, *Romanian Reports in Physics* 45, 153-163 (1993).

A. Manolescu and T. Stanescu, Homogeneous-inhomogeneous transitions in a Landau level with spin splitting, *Z. Phys. B* 94, 87-90 (1994).

A. Manolescu and R. R. Gerhardtts, Exchange enhanced spin splitting in a two-dimensional electron system with lateral modulation, *Phys. Rev. B* 51, 1703-1713 (1995).

A. Manolescu, Density profile in a weakly modulated 2D system in a magnetic field, *Phys. Rev. B* 52, 2831-2837 (1995).

A. Manolescu, R.R. Gerhardtts, M. Tornow, D. Weiss, K.v.Klitzing, and G. Weimann, Coulomb interaction effects on the magnetoconductivity of laterally modulated 2D electron systems, *Surf. Sci.* 361/362, 513 (1996).

M. Tornow, D. Weiss, A. Manolescu, R. Menne, K.v. Klitzing, and G. Weimann, Even-odd filling-factor switching in one-dimensional lateral superlattices, *Phys. Rev. B* 54, 16397-16400 (1996).

A. Manolescu and R.R. Gerhardtts, Coulomb effects on the magneto-transport of a 2D electron gas in a lateral superlattice: A screened Hartree-Fock calculation, in *Proceedings of The 12-th International Conference on the Applications of High Magnetic Fields in Semiconductor Physics (Wuerzburg 1996)*, edited by G. Landwehr and W. Ossau, p.319-322 (World Scientific, 1997).

A. Aldea, P. Gartner, A. Manolescu, and M. Nita, Specific plateaus of the quantum Hall effect induced by an external bias, *Phys. Rev. B* 55, 13389R (1997).

A. Manolescu and R. R. Gerhardtts, Coulomb effects on the quantum transport of a two-dimensional electron system in periodic electric and magnetic fields, *Phys. Rev. B* 56, 9707-9718 (1997).

U. Gossmann, A. Manolescu, and R. R. Gerhardtts, Density modulation and electrostatic self-consistency in a two-dimensional electron gas in a periodic quantizing magnetic field, *Phys. Rev. B* 57, 1680-1689 (1998).

A. Manolescu and V. Gudmundsson, The far infra-red absorption of short period quantum wires and the transition from one to two dimensions, *Phys. Rev. B* 57, 1668-1673 (1998).

A. Manolescu and V. Gudmundsson, Collective modes and the farinfrared absorption of the two-dimensional electron gas in a periodic quantizing magnetic field, *Superlattices and Microstructures* 23, 1169-1180 (1998).

A. Manolescu, S. Zworschke, M. Nita, U. J. Gossmann, and R. R. Gerhardtts, Quantum analog of channeled electron trajectories in periodic magnetic and electric fields, 13-th International Conference on Magnetic Fields in Semiconductor Physics (Nijmegen 1998), *Physica B* 256-258, 375-379 (1998).

A. Manolescu and V. Gudmundsson, Memorization of short-range potential fluctuations in Landau levels, *Phys. Rev. B* 59, 5426-5430 (1999).

R. Lungu and A. Manolescu, The Floquet solution for systems with quadratic form Hamiltonians, *Physica Scripta* 59, 331-338 (1999).

S. D. M. Zworschke, A. Manolescu, and R. R. Gerhardtts, Planar cyclotron motion in unidirectional superlattices defined by strong magnetic and electric fields: Traces of classical orbits in the energy spectrum, *Phys. Rev. B* 60, 5536 (1999).

A. Aldea, A. Manolescu, and V. Moldoveanu, Coulomb effects on the transmittance of open quantum dots in a tight-binding model,

Ann. Phys. (Leipzig) 8, SI17-SI20 (1999).

S. I. Erlingsson, A. Manolescu, and V. Gudmundsson, Finite size effects in the magnetization of periodic mesoscopic systems, *Physica E* 6, 763 (2000).

V. Gudmundsson, S. I. Erlingsson, and A. Manolescu, Magnetization in short-period mesoscopic electron systems, *Phys. Rev. B* 61, 4835 (2000).

A. Manolescu and V. Gudmundsson, Hysteresis effect due to the exchange Coulomb interaction in short-period superlattices in tilted magnetic fields, *Phys. Rev. B* 61, R7858 (2000).

R. Lungu and A. Manolescu, The Perturbative Floquet solution for quasi-free electrons, *Physica Scripta* 62, 97-105 (2000).

R. Lungu and A. Manolescu, Many-body fermion systems in the Floquet formalism, *Physica Scripta* 62, 433-445 (2000).

V. Moldoveanu, A. Aldea, A. Manolescu, and M. Nita, Coulomb effects on the transport properties of quantum dots in strong magnetic field, *Phys. Rev. B* 63, 045301 (2001).

G. Nachtwei, A. Manolescu, N. Nestle, and H. Kunzel, Bistable resistance transition in a ferromagnetic quantum Hall system, *Springer Proceedings in Physics* 87, 997 (2001) (ICPS25, Osaka, 2000).

G. Nachtwei, A. Manolescu, N. Nestle, and H. Kunzel, Bistable resistance switching in a ferromagnetic quantum Hall system induced by exchange enhancement, *Phys. Rev. B* 63, 045306 (2001).

A. Manolescu, R. R. Gerhardt, M. Suhrke, and U. Roessler, Anisotropic scattering and quantum magnetoresistivities of a periodically modulated 2D electron gas, *Phys. Rev. B* 63, 115322(2001).

I. Meinel, D. Grundler, D. Heitmann, A. Manolescu, and V. Gudmundsson, Enhanced magnetization at integer quantum Hall states, *Phys. Rev. B* 64, 121306(R) (2001).

A. Manolescu and B. Tanatar, Plasmons and the drag effect in a strong magnetic field, *Physica E* 13, 80 (2002).

G. Nachtwei, A. Manolescu, N. Nestle and H. Kunzel, Ferromagnetism in a quantum Hall system due to exchange enhancement in a GaInAs quantum well, *Physica E* 12, 20 (2002).

R. Lungu and A. Manolescu, Two-dimensional electron system in electromagnetic radiation, *Int. J. Mod. Phys. B* 15, 4245 (2001).

V. Gudmundsson, A. Manolescu, R. Krahne, and D. Heitmann, From single dots to interacting arrays, in "Nano-Physics and Bio-Electronics: A New Odyssey", edited by T. Chakraborty, F. Peeters, and U. Sivan, p.213-235 (Elsevier, 2002).

M. Valín-Rodríguez, A. Puente, L. Serra, V. Gudmundsson, and A. Manolescu, Characterization of Bernstein modes in quantum dots, *European Physical Journal B* 28, 111 (2002).

G. Vasile, V. Gudmundsson, and A. Manolescu, Orbital and spin magnetization of a confined electronic system in the transition between a quantum dot and a ring, 15th International Conference on High Magnetic Fields in Semiconductor Physics, August 2002, Institute of Physics Conference Series 171, A-11, Editorsr A. R. Long and J. H. Davies, IOP (Bristol - Philadelphia) (2003).

A. Aldea, V. Moldoveanu, M. Nita, A. Manolescu, V. Gudmundsson, and B. Tanatar The orbital magnetization of single and double quantum dots in a tight binding model, *Phys. Rev. B* 67, 035324 (2003).

V. Gudmundsson, C. S. Tang, and A. Manolescu, Non-adiabatic current generation in a finite width semiconductor ring, *Phys. Rev. B* 67, 161301 (2003).

V. Gudmundsson, C. S. Tang, and A. Manolescu, Impurity and spin effects on the magneto-spectroscopy of a THz-modulated nanostructure, *Phys. Rev. B* 68, 165343 (2003).

S. S. Gylfadottir, V. Gudmundsson, C. S. Tang, A. Manolescu, Non-adiabatic Current Excitation in Quantum Rings, *Physica Scripta* T114, 41(2004).

J. H. Bardarson, I. Magnusdottir, G. Gudmundsdottir, C. S. Tang, A. Manolescu, V. Gudmundsson, Coherent electronic transport in a multimode quantum channel with Gaussian-type scatterers, *Phys. Rev. B* 70 245308 (2004).

S. S. Gylfadottir, M. Nita, V. Gudmundsson, A. Manolescu, Net current generation in a 1D quantum ring at zero magnetic field, *Physica E* 27, 278 (2005).

V. Gudmundsson, G. Gudmundsdottir, J. H. Bardarson, I. Magnúsdóttir, C. S. Tang, and A. Manolescu, Multi-mode transport through a quantum nanowire with two embedded dots, *The European Physical Journal B* 45, 339 (2005).

V. Gudmundsson, Y. Y. Lin, C. S. Tang, V. Moldoveanu, J. H. Bardarson, and A. Manolescu, Transport through a quantum ring, a dot and a barrier embedded in a nanowire in magnetic field, *Phys. Rev. B* 71, 235302 (2005).

V. Moldoveanu, M. Tolea, V. Gudmundsson, and A. Manolescu, The Fano regime of one-dot Aharonov-Bohm interferometers, *Phys. Rev. B* 72 085338 (2005).

V. Gudmundsson, C. S. Tang, and A. Manolescu, A state with negative binding energy induced by coherent transport in a quantum wire, *Phys. Rev. B* 72, 153306 (2005).

V. Moldoveanu, V. Gudmundsson, and A. Manolescu, Transient regime in non-linear transport through many-level quantum dots, *Phys. Rev. B* 76, 085330 (2007).

V. Moldoveanu, V. Gudmundsson, and A. Manolescu, Non-adiabatic transport in a quantum dot turnstile, preprint cond-mat/07060968, *Phys. Rev. B* in press (2007).